Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry

Eun Joo Chung, Sunmin Lee, Edward A. Sausville, Qin Ryan, Judith E. Karp, Ivana Gojo, William G. Telford, Min Jung Lee, Hye Sik Kong, Jane B. Trepel

Research output: Contribution to journalArticlepeer-review


Histone deacetylase (HDAC) inhibitors are a promising new class of anticancer drug. The aim of this study was to develop a versatile and sensitive technique for the pharmacodynamic (PD) assessment of HDAC inhibitor activity as monotherapy and in combination therapy. A multiparameter flow cytometric assay was developed initially in healthy donor lymphocytes and leukemia cell lines, and then tested in peripheral blood of solid tumor patients and in bone marrow aspirates of leukemia patients on phase I trials of the HDAC inhibitor MS-275. A technique was developed that allows highly sensitive single parameter determination of HDAC inhibitor activity in as little as 50 μl of whole blood. Multiparameter analysis enabled correlation on a single cell basis of protein acetylation with biologically relevant markers including cell lineage antigens, an apoptosis marker, and PD markers of other anti-cancer agents. The level of protein acetylation can be readily detected and quantified in peripheral blood or in bone marrow aspirates by flow cytometric analysis. The technique described has significant advantages for the PD assessment of HDAC inhibitors as monotherapy and as a component of combination therapy trials.

Original languageEnglish (US)
Pages (from-to)397-406
Number of pages10
JournalAnnals of Clinical and Laboratory Science
Issue number4
StatePublished - Sep 2005


  • Flow cytometry
  • HDAC
  • Multiparameter
  • Pharmacodynamic analysis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry'. Together they form a unique fingerprint.

Cite this